These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37365540)

  • 21. Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.
    Chen H; Ma X; Liu J; Yang Y; He Y; Fang Y; Wang L; Fang J; Zhao J; Zhuo M
    Clin Transl Oncol; 2024 Jul; 26(7):1664-1673. PubMed ID: 38329610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
    Liu ZL; Wang B; Liu JZ; Liu WW
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1076-S1083. PubMed ID: 30539849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
    Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
    PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
    Rudin CM; Awad MM; Navarro A; Gottfried M; Peters S; Csőszi T; Cheema PK; Rodriguez-Abreu D; Wollner M; Yang JC; Mazieres J; Orlandi FJ; Luft A; Gümüş M; Kato T; Kalemkerian GP; Luo Y; Ebiana V; Pietanza MC; Kim HR;
    J Clin Oncol; 2020 Jul; 38(21):2369-2379. PubMed ID: 32468956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China.
    Long Y; Wang H; Xie X; Li J; Xu Y; Zhou Y
    BMJ Open; 2024 Apr; 14(4):e077090. PubMed ID: 38582540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis.
    Wang S; Li Y; Liu Z; Tian W; Zeng Y; Liu J; Zhang S; Peng Y; Wu F
    Lung Cancer; 2023 Apr; 178():47-56. PubMed ID: 36774774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
    Shao T; Zhao M; Liang L; Tang W
    BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Efficacy and Safety in First-Line Treatment Methods for Extensive-Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy.
    Zhang T; Tao L; Chen Y; Zhang S; Liu Y; Li Y; Wang R
    Clin Respir J; 2024 Aug; 18(8):e13819. PubMed ID: 39118429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis.
    Yao Y; Li B; Song R; Yang L; Zou B; Wang L
    Radiat Oncol; 2024 Feb; 19(1):25. PubMed ID: 38413988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.
    Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
    Curr Oncol; 2019 Jun; 26(3):e372-e384. PubMed ID: 31285682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
    Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
    J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis.
    Kang S; Wang X; Zhang Y; Zhang B; Shang F; Guo W
    Front Oncol; 2021; 11():740091. PubMed ID: 35127468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
    Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
    Amarasena IU; Chatterjee S; Walters JA; Wood-Baker R; Fong KM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006849. PubMed ID: 26233609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
    Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
    Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
    Paz-Ares L; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Musso E; Havel L; Bondarenko I; Losonczy G; Conev N; Mann H; Dalvi TB; Jiang H; Goldman JW
    ESMO Open; 2022 Apr; 7(2):100408. PubMed ID: 35279527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
    Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
    JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer.
    Mi S; Yang Y; Liu X; Tang S; Liang N; Sun J; Liu C; Ren Q; Lu J; Hu P; Zhang J
    Clin Transl Oncol; 2024 Sep; 26(9):2339-2350. PubMed ID: 38598001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
    Wu JJ; Huang JW; Hsu KH; Huang YH; Chen KC; Tseng JS; Yang TY; Chang GC
    Anticancer Drugs; 2022 Nov; 33(10):e842-e849. PubMed ID: 36206101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
    Ding D; Hu H; Li S; Zhu Y; Shi Y; Liao M; Liu J; Tian X; Liu A; Huang J
    J Natl Compr Canc Netw; 2021 Aug; 19(10):1141-1147. PubMed ID: 34348237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.